Long-term Remission by Brentuximab Vedotin for Non-mediastinal Gray Zone Lymphoma Refractory to Autologous Stem Cell Transplantation

Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long‑term remission

“…Recently, in the AETHERA trial, BV maintenance after autologous SCT (ASCT) had a statistically significant prognostic impact in patients with R/R cHL (8). However, only few studies showed that BV + conventional chemotherapy is effective for treatment-naïve GZL or BV maintenance therapy for R/R GZL (5,9,10). Herein, we report a patient with R/R GZL that is highly resistant to conventional chemotherapy and radiation therapy (RT).…”